Oncotarget is Again on MEDLINE

(2:21)

Oncotarget: Inhibit oral squamous carcinoma cell migration and viability

(7:58)

Oncotarget: Addiction to Runx1 is partially attenuated by loss of p53

(4:9)

Oncotarget is proud to have supported Roswell Park's \

(2:47)

Oncotarget | Oncotarget's Top-10 Most-Viewed Papers in 2021

(1:30)

Tumor Immunoprofiling and the Tumor Microenvironment (Immunotherapy Documentary Part II)

(34:54)

Glyphosate \u0026 Cancer: An honest look at the science

(19:44)

Oncotarget: Transcription and proliferation of human tumor cells

(7:54)

How do natural killer cells target cancer?

(4:10)

HER3: A Vital Target in Cancer Treatment | Oncotarget

(8:49)

Oncotarget: Osteoprotegerin rich tumor microenvironment: implications in breast cancer

(4:54)

What tumors eat -- and how to poison them | Dr. Christal Sohl | TEDxTulsaCC

(10:15)

Lung Bulla

(3:46)

Liver Cancer Patient Donald Melillo

(11:)

Oncotarget: Significant differences in biomarker expression in pancreatic cancer

(11:36)

Oncotarget | Side Effects of Cancer Treatments on Learning, Memory, Genes

(1:1econd)

Oncotarget: A New Class of Radiosensitizers for Glioblastoma

(50)

Pitfalls of FDA-Approved Germline Cancer Predisposition Tests | Oncotarget

(1:57)

Dark Side of PLK1: Implications for Cancer and Genomic Instability | Oncotarget

(2:)

Oncotarget: Targeted Ovarian Cancer Treatment

(50)

Oncotarget: The Role of RNA Modification Regulatory Proteins in Melanoma

(59)

Variants and Polymorphisms in Bladder Cancer | Oncotarget

(59)

Oncotarget: The Oncopig Cancer Model and Liver Cancer

(51)

Oncotarget: Combination Therapeutics Inhibit Breast Cancer Resistance

(41)

Oncotarget | NOTCH1 Variants in Triple-Negative Breast Cancer

(1:)

Oncotarget | Table of Contents - Volume 12, Issue 26

(57)

Genomics Has More to Reveal | Oncotarget

(1:27)

Oncotarget: ONC201, TRAIL, and Breast Cancer

(52)

Oncotarget: Expanding Research Impact with TrendMD

(48)